Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07311863
EARLY_PHASE1

UGX202 Injection in Patients With Advanced Retinitis Pigmentosa

Sponsor: Suzhou UgeneX Therapeutics Co., Ltd.

View on ClinicalTrials.gov

Summary

The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.

Official title: Study to Evaluate the Safety and Preliminary Efficacy of UGX202 Injection in Patients With Advanced Retinitis Pigmentosa

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2026-01

Completion Date

2027-03

Last Updated

2025-12-31

Healthy Volunteers

No

Interventions

GENETIC

UGX202 injection

Comparison of different dosages of UGX202

Locations (1)

Eye & ENT Hospital of Fudan University

Shanghai, Shanghai Municipality, China